STOCK TITAN

Fortress Biotech Inc - FBIO STOCK NEWS

Welcome to our dedicated news page for Fortress Biotech (Ticker: FBIO), a resource for investors and traders seeking the latest updates and insights on Fortress Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fortress Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fortress Biotech's position in the market.

Rhea-AI Summary
Journey Medical enters exclusive license agreement with Maruho Co., Ltd. for Qbrexza in multiple territories
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.68%
Tags
none
-
Rhea-AI Summary
Journey Medical enters exclusive license agreement with Maruho Co., Ltd. for Qbrexza in multiple territories
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
Rhea-AI Summary
Fortress Biotech, Inc. (Nasdaq: FBIO) announced total net revenue of $17.4 million in Q2 2023, a 40% increase from Q1 2023. Positive results were achieved in Phase 3 clinical trials for DFD-29 and cosibelimab. Two NDA submissions for DFD-29 and CUTX-101 are anticipated in H2 2023. The PDUFA goal date for cosibelimab is January 3, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
earnings
Rhea-AI Summary
Journey Medical Corporation (Nasdaq: DERM) announced a 41% increase in total net revenues to $17.2 million in Q2 2023, and positive topline results from two Phase 3 clinical trials evaluating DFD-29 for papulopustular rosacea treatment. The company plans to submit an NDA to the FDA for DFD-29 in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
earnings
-
Rhea-AI Summary
Journey Medical Corporation (Nasdaq: DERM) announced a 41% increase in total net revenues to $17.2 million in Q2 2023, and positive topline results from two Phase 3 clinical trials evaluating DFD-29 for papulopustular rosacea treatment. The company plans to submit an NDA to the FDA for DFD-29 in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
conferences
Rhea-AI Summary
DERM: Journey Medical Corporation to Discuss Positive Topline Clinical Data and Financial Results in Upcoming Conference Call on August 8, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
earnings
-
Rhea-AI Summary
DERM: Journey Medical Corporation to Discuss Positive Topline Clinical Data and Financial Results in Upcoming Conference Call on August 8, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
earnings
-
Rhea-AI Summary
Journey Medical Corporation will release its second quarter 2023 financial results during the week of August 7, 2023. The company will also host a conference call to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
earnings
Rhea-AI Summary
Journey Medical Corporation will release its second quarter 2023 financial results during the week of August 7, 2023. The company will also host a conference call to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Fortress Biotech Inc

Nasdaq:FBIO

FBIO Rankings

FBIO Stock Data

36.75M
6.58M
28.08%
25.68%
9.42%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About FBIO

fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.